Stock · ISRG · Healthcare
United States · Large Cap · listed since 2000 · Revenue 12 mo. $11.6B
Price as of 11/06/2026
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally.
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
Original text from the data provider
Summary
51.9 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €2.2B (2025), it supports €24.8B. The remaining €122.9B of the market value assume it grows 24.9% a year for 10 years and not at all afterwards.
Required FCF growth per year
24.9%
no growth afterwards
Price to operating cash flow 38.9×, below its usual range.
Middle half of 20 quarters: 51.1× to 68.0×, median 63.4×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q2 → Q3 2026
4 more unchanged: Revenue, 12 mo., Gross margin, Net debt, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 16.02% | 11.52% | Rank 69 |
| Return on capital (Greenblatt) | 22.46% | 32.55% | Rank 30 |
| EBIT margin | 29.27% | 18.31% | Rank 84 |
| FCF margin | 24.75% | 14.12% | Rank 84 |
| Gross margin | 66.00% | 60.99% | Rank 57 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 20.51% | 8.04% | Rank 85 |
| Earnings growth, 3 years per year | 29.18% | 5.44% | Rank 80 |
| Earnings growth, 5 years per year | 21.79% | 7.00% | Rank 86 |
| Sustainable growth (ROE × retained earnings) | 5.36% | 3.66% | Rank 67 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 1.74% | 2.90% | Rank 23 |
| FCF yield | 1.51% | 3.63% | Rank 17 |
| EV/saleslower is better | 15.79 | 4.03 | Rank 8 |
| EV/EBITlower is better | 53.97 | 21.73 | Rank 5 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | −26.95% | 8.66% | Rank 10 |
| Share price, 6 months | 1.09% | 24.27% | Rank 16 |
| Share price, 3 months | 24.66% | 15.42% | Rank 80 |
| Distance from 52-week high | −23.62% | −7.35% | Rank 17 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −4.26% | 0.30% | Rank 84 |
| Change in share countlower is better | 0.19% | 0.00% | Rank 28 |
| Dividend streak in yearsdoes not count towards the rank | – | 10 | |
| Price reaction to results, market-adjusted | −2.78% | 0.05% | Rank 22 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 86.39% | 48.40% | Rank 97 |
| Net debt/EBITDAlower is better | −1.41 | 1.11 | Rank 88 |
| Debt to equitylower is better | 0.02 | 0.48 | Rank 92 |
| Volatility, 1 yearlower is better | 35.42% | 31.42% | Rank 38 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF | Shares | Net debt |
|---|---|---|---|---|---|
| 2016 | 2.7 | 35.0% | $989.0M | 354M | −$4.8B |
| 2017 | 3.1 | 33.7% | $953.2M | 349M | −$3.8B |
| 2018 | 3.7 | 32.2% | $982.2M | 356M | −$857.9M |
| 2019 | 4.5 | 30.7% | $1.2B | 359M | −$1.1B |
| 2020 | 4.4 | 24.1% | $1.1B | 361M | −$1.6B |
| 2021 | 5.7 | 31.9% | $1.7B | 366M | −$1.2B |
| 2022 | 6.2 | 25.4% | $958.4M | 362M | −$1.6B |
| 2023 | 7.1 | 24.8% | $749.6M | 357M | −$2.8B |
| 2024 | 8.4 | 28.1% | $1.3B | 362M | −$1.9B |
| 2025 | 10.1 | 29.3% | $2.5B | 363M | −$3.1B |
4 of 7 StockScorer Score rules met · How the score is built
Intuitive Surgical Inc mainly meets criteria in the Growth category. Result from 18 strategies checked.
Intuitive Surgical Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
4 of 7 rules met
6 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Intuitive Surgical Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 57.5 | 30.0 |
| P/B ratio | 9.2 | 4.8 |
| Return on equity (ROE) | 16.0% | 11.5% |
| Equity ratio | 86.4% | 48.4% |
| Debt-to-equity (D/E) | 0.02 | 0.48 |
| Dividend yield | – | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| ISRG | Intuitive Surgical Incthis page | |
| BDX | Becton Dickinson and Company | Low2.7 |
| MDLN | Medline Inc. Class A Common Stock | locked |
| EL.PA | EssilorLuxottica S. A. | Low3.6 |
| 7741.T | Hoya Cor | locked |
| ALC.SW | Alcon AG | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.